MedPage Today’s latest roundup of public-health and biotech news begins with a retraction: Science Translational Medicine pulled a 2022 mouse study that reported COVID-19 vaccination elicits broad neutralizing antibodies, citing some fabricated data. The same roundup notes more than 1,200 measles cases confirmed in Pennsylvania and Kenya’s second confirmed Ebola case, underscoring ongoing infectious-disease pressures.
On the regulatory side, the FDA launched an initiative to build a tailored framework for accelerating rare disease drug development in small patient populations. It also approved an expanded indication for nogapendekin alfa inbakicept-pmln (Anktiva) for BCG-unresponsive non-muscle invasive bladder cancer. Meanwhile, Par Health recalled 22 lots of argatroban injection because of foreign particulates, including cellulose, polystyrene, polyethylene terephthalate, stopper material, and potential stainless steel.
The roundup also covers patient-safety signals: a cross-sectional study in The BMJ found adverse event summary reports in the FDA’s manufacturer and user facility device experience database are often incomplete, inaccurate, and delayed, and a JAMA Psychiatry study linked legalized online sports betting with increases in outpatient and prescription mental healthcare use. Since this article is based on a single source, there are no differing reports to reconcile; the items appear as presented by MedPage Today.